Share on StockTwits

Shares of Rite Aid (NYSE:RAD) have earned an average recommendation of “Buy” from the ten brokerages that are currently covering the stock, Analyst RN reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $7.50.

Shares of Rite Aid (NYSE:RAD) opened at 6.34 on Thursday. Rite Aid has a one year low of $3.35 and a one year high of $8.62. The stock’s 50-day moving average is $6.69 and its 200-day moving average is $6.97. The company has a market cap of $6.108 billion and a P/E ratio of 36.65. Rite Aid also was the recipient of a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 38,718,163 shares, a growth of 28.3% from the July 31st total of 30,166,576 shares. Currently, 4.0% of the company’s stock are sold short. Based on an average trading volume of 24,308,641 shares, the days-to-cover ratio is presently 1.6 days.

Rite Aid (NYSE:RAD) last posted its quarterly earnings results on Thursday, June 19th. The company reported $0.04 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.05 by $0.01. The company had revenue of $6.47 billion for the quarter, compared to the consensus estimate of $6.43 billion. During the same quarter in the prior year, the company posted $0.09 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. On average, analysts predict that Rite Aid will post $0.35 earnings per share for the current fiscal year.

RAD has been the subject of a number of recent research reports. Analysts at Jefferies Group cut their price target on shares of Rite Aid from $7.50 to $6.50 in a research note on Friday, August 8th. Separately, analysts at S&P Equity Research downgraded shares of Rite Aid to a “sell” rating in a research note on Friday, June 6th. Finally, analysts at Goldman Sachs reiterated a “buy” rating on shares of Rite Aid in a research note on Thursday, June 5th.

Rite Aid Corporation is a retail drugstore chain in the United States. In the Company’s stores, it sells prescription drugs and a range of other merchandise, which it calls front end products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.